Lamy Patrick
Officer at AKRO
- Sold, on record
- $1.5M
- Dollars the filings state
- Form 4 sales
- 12
- Latest Jul 1, 2025
- Form 144 notices
- 5
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- AKROAkero Therapeutics, Inc.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 144 notice AKRONoticeMay 22, 2025 2025
Filed to sell 10,000 shares ($484k)
Lamy Patrick, Officer
10b5-1 plan10x usual sizeFiling
- 2 Form 4 sale AKROUnusualMay 22, 2025 same day
Sold 4,000 shares at $50.00 ($200k)
Lamy Patrick, Senior VP, Commercial Strategy
10b5-1 planSold 10.7% of holdings ($1.9M position)33,492 shares left4x usual sizeFollows a Form 144Filing
- 3 Form 4 sale AKROUnusualJun 2, 2025 +11 days
Sold 4,000 shares at $50.32 ($201k)
Lamy Patrick, Senior VP, Commercial Strategy
10b5-1 planSold 10.7% of holdings ($1.9M position)33,492 shares left4x usual sizeFollows a Form 144Filing
- 4 Form 4 sale AKRONo planJun 10, 2025 +8 days
Sold 919 shares at $54.00 ($50k)
Lamy Patrick, Senior VP, Commercial Strategy
No 10b5-1 planSold 2.7% of holdings ($1.8M position)32,573 shares left0.4x usual sizeFollows a Form 144Filing
- 5 Form 4 sale AKRORoutineJun 16, 2025 +6 days
Sold 2,000 shares at $54.14 ($108k)
Lamy Patrick, Senior VP, Commercial Strategy
10b5-1 planSold 5.8% of holdings ($1.9M position)32,573 shares left2x usual sizeFollows a Form 144Filing
- 6 Form 4 sale AKRONo planJun 20, 2025 +4 days
Sold 875 shares at $54.59 ($48k)
Lamy Patrick, Senior VP, Commercial Strategy
No 10b5-1 planSold 2.7% of holdings ($1.8M position)31,698 shares left0.6x usual sizeFiling
- 7 Form 144 notice AKRONoticeJul 1, 2025 +11 days
Filed to sell 2,000 shares ($107k)
Lamy Patrick, Officer
10b5-1 plan2x usual sizeFiling
- 8 Form 4 sale AKRORoutineJul 1, 2025 same day
Sold 2,000 shares at $52.88 ($106k)
Lamy Patrick, Senior VP, Commercial Strategy
10b5-1 planSold 6.3% of holdings ($1.7M position)29,891 shares left2x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (17)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | Jul 3, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 2,000 | $106k | 6.3% | Routine | SEC |
| Jul 1, 2025 | Jul 1, 2025 | AKRO | Officer | Form 144 notice | 2,000 | $107k | Notice | SEC | |
| Jun 20, 2025 | Jun 20, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 875 | $48k | 2.7% | No plan | SEC |
| Jun 16, 2025 | Jun 20, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 2,000 | $108k | 5.8% | Routine | SEC |
| Jun 10, 2025 | Jun 12, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 919 | $50k | 2.7% | No plan | SEC |
| Jun 2, 2025 | Jun 4, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 4,000 | $201k | 10.7% | Unusual | SEC |
| May 22, 2025 | May 23, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 4,000 | $200k | 10.7% | Unusual | SEC |
| May 22, 2025 | May 22, 2025 | AKRO | Officer | Form 144 notice | 10,000 | $484k | Notice | SEC | |
| May 7, 2025 | May 9, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 8,000 | $340k | 19.3% | Unusual | SEC |
| Apr 7, 2025 | Apr 7, 2025 | AKRO | Officer | Form 144 notice | 8,000 | $294k | Notice | SEC | |
| Mar 3, 2025 | Mar 5, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 1,000 | $48k | 2.9% | Routine | SEC |
| Jan 27, 2025 | Jan 29, 2025 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 5,000 | $285k | 13.0% | Unusual | SEC |
| Jan 27, 2025 | Jan 27, 2025 | AKRO | Officer | Form 144 notice | 6,000 | $157k | Notice | SEC | |
| Dec 16, 2024 | Dec 18, 2024 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 1,000 | $29k | 2.8% | Routine | SEC |
| Dec 16, 2024 | Dec 16, 2024 | AKRO | Officer | Form 144 notice | 1,000 | $29k | Notice | SEC | |
| Dec 10, 2024 | Dec 12, 2024 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 925 | $28k | 4.9% | No plan | SEC |
| Jun 11, 2024 | Jun 13, 2024 | AKRO | Senior VP, Commercial Strategy | Form 4 sale | 569 | $13k | 3.0% | No plan | SEC |